4 results
To evaluate the efficacy of BEM compared with placebo in reducing all cause hospitalization or all-cause death in COVID-19 outpatients receiving only supportive care.
The aim of this global Phase III study is to investigate the use of tezepelumab as a treatment for patients with EoE. This study will evaluate the efficacy and safety of tezepelumab 210 mg every 4 weeks (Q4W) and tezepelumab 420mg Q4W administered…
To evaluate the effect of tezepelumab as compared with placebo on COPD exacerbations in subjects with moderate to very severe COPD
The purpose of this study is to determine the sustained benefit on safety and efficacy of AMG 334 compared to oral prophylactics in episodic migraine patients who have previously failed 1 to 2 prophylactic migraine treatments and therefore have a…